KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

NovoCure (NVCR) Shares Outstanding (Diluted Average) (2018 - 2025)

NovoCure's Shares Outstanding (Diluted Average) history spans 8 years, with the latest figure at $111.5 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Diluted Average) rose 3.37% year-over-year to $111.5 million; the TTM value through Dec 2025 reached $111.5 million, up 3.37%, while the annual FY2025 figure was $111.5 million, 3.37% up from the prior year.
  • Shares Outstanding (Diluted Average) for Q4 2025 was $111.5 million at NovoCure, roughly flat from $111.3 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $111.6 million in Q2 2025 and bottomed at $102.6 million in Q1 2021.
  • The 5-year median for Shares Outstanding (Diluted Average) is $106.1 million (2023), against an average of $106.5 million.
  • The largest annual shift saw Shares Outstanding (Diluted Average) dropped 6.48% in 2021 before it grew 3.8% in 2025.
  • A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $103.4 million in 2021, then increased by 1.19% to $104.7 million in 2022, then increased by 1.65% to $106.4 million in 2023, then increased by 1.36% to $107.8 million in 2024, then increased by 3.37% to $111.5 million in 2025.
  • Per Business Quant, the three most recent readings for NVCR's Shares Outstanding (Diluted Average) are $111.5 million (Q4 2025), $111.3 million (Q3 2025), and $111.6 million (Q2 2025).